Neutrophil-activating protein ENA-78 and IL-8 exhibit different patterns of expression in lipopolysaccharide- and cytokine-stimulated human monocytes

J Immunol. 1997 Apr 15;158(8):3888-94.

Abstract

The production of epithelial neutrophil-activating protein-78 (ENA-78) by normal human monocytes was studied in comparison with IL-8 upon stimulation with various stimuli. LPS at 100 ng/ml was a strong inducer of ENA-78, yielding a delayed up-regulation of steady state mRNA peaking at 24 h and causing a long-lasting ENA-78 protein secretion starting 20 h after induction. As shown by specific ELISA and immunoprecipitation, ENA-78 secretion by monocytes was not down-regulated for up to 72 h. Thus, ENA-78 production becomes effective when IL-8 synthesis is shut off, since IL-8 mRNA peaks at 4 to 12 h and approaches background levels at about 16 h. Induction of steady state ENA-78 mRNA by proinflammatory cytokines IL-1beta (10 ng/ml) and TNF-alpha (100 ng/ml) was weaker than that by LPS and yielded a biphasic kinetic with a first maximum at 8 to 12 h and a second at 20 to 28 h. Steady state IL-8 mRNA induced by LPS, IL-1beta, or TNF-alpha was superinduced or unchanged in the presence of cycloheximide (10 microg/ml). In contrast, ENA-78 mRNA was completely abrogated, suggesting the involvement of a newly synthesized protein intermediate necessary for ENA-78 up-regulation. Dexamethasone treatment reduced ENA-78 mRNA and protein levels by 60% of the LPS control level. This inhibition was identical when dexamethasone was added 8 h after LPS induction. These results demonstrate significant differences in the production of monocyte-derived IL-8 and ENA-78 and thus may suggest different roles for the two chemokines in acute or chronic inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Cells, Cultured
  • Chemokine CXCL5
  • Chemokines, CXC*
  • Cytokines / pharmacology*
  • Dexamethasone / pharmacology*
  • Gene Expression Regulation / drug effects*
  • Humans
  • Interleukin-8 / analogs & derivatives*
  • Interleukin-8 / biosynthesis*
  • Lipopolysaccharides / pharmacology*
  • Monocytes / drug effects
  • Monocytes / metabolism*

Substances

  • Anti-Inflammatory Agents
  • CXCL5 protein, human
  • Chemokine CXCL5
  • Chemokines, CXC
  • Cytokines
  • Interleukin-8
  • Lipopolysaccharides
  • Dexamethasone